T-Therapeutics
T-Therapeutics is a 2022 University of Cambridge spin-out based in Cambridge, UK.
Position in SVTRnew
Snapshot 2026-11-06- Startup SignalsTop 25%
- Life SciencesTop 25%
- AI for ScienceTop 25%
- Drug DiscoveryTop 25%
About
T-Therapeutics is a 2022 University of Cambridge spin-out based in Cambridge, UK. Its OpTiMus fully humanised TCR mouse platform generates fully human T-cell receptors, which it screens using single-cell genomics and machine learning and engineers into TCR-CD3 bispecific T-cell engagers against intracellular targets in solid tumours and autoimmune disease.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 12
Investor· 10
Founders / team· 3
Funding history
- 2026-11-05Series B$133M
Investors · Advent Life Sciences, British Business Bank, Johnson & Johnson Innovation, Samsara BioCapital, M Ventures, Eli Lilly, Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi, Tencent, BGFSource · sofinnovapartners.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- T-Therapeutics
T-Therapeutics is a 2022 University of Cambridge spin-out based in Cambridge, UK.
Series B · $224M · 2026-11
$224M
United States
BusinessLatest roundTotal raisedDate- Electra Therapeutics
Develops antibody drugs targeting SIRP.
IPO · $302M · 2026-09
$302M - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - Cartography Biosciences
Single-cell multi-omics + AI tumor antigen atlas platform; develops in-house antibody-based cancer immunotherapies and out-licenses targets
Series B · $124M · 2025-10
$124M
China
BusinessLatest roundTotal raisedDate- Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerati…
Seed · $25M · 2026-08
$25M - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M
Europe
BusinessLatest roundTotal raisedDate- Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 21 at a nearby stage · 3 in Western Europe
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 21 at a nearby stage · 1 in Western Europe
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 12 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 7 at a nearby stage · 3 in Western Europe
Request intro →GV
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.